A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
© 2018 The Authors Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation off...
Saved in:
Main Authors: | Maria Domenica Cappellini, John B. Porter, Vip Viprakasit, Ali T. Taher |
---|---|
Other Authors: | American University of Beirut Medical Center |
Format: | Review |
Published: |
2019
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/46572 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo
by: Ali T. Taher, et al.
Published: (2018) -
An overview of current treatment strategies for β-thalassemia
by: Maria Domenica Cappellini, et al.
Published: (2018) -
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study
by: Ali T. Taher, et al.
Published: (2018) -
When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
by: A. T. Taher, et al.
Published: (2018) -
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
by: Wai Cheng Foong, et al.
Published: (2018)